In a mouse model of dextran sulphate sodium (DSS)-induced colitis, TRPM2 deficiency reduces the production of the CXCL2 chemokine, resulting in diminished neutrophilic influx to the colon, and protects against colon inflammation, suggesting that pharmacological inhibition of TRPM2 might be a new therapeutic strategy for treating IBD (Yamamoto et al., 2008; Knowles et al., 2013; Fig. 1). The gene discussed is TRPM2; the disease is inflammatory bowel disease.